HERNEXEOS Lung Cancer Treatment: First FDA Appr...

By HEOR Staff Writer

March 2, 2026

FDA Greenlights HERNEXEOS Lung Cancer Treatment as First-Line Option HERNEXEOS lung cancer treatment (zongertinib tablets), developed by
KEYTRUDA Padcev MIBC Survival: New Era in Treatment Revealed by KEYNOTE-B15 T...
Novartis Drug Discovery Innovation: Advancing Global Health Through Strategic...
Infarmed Regulatory Activity: January 2026 Highlights and Impacts on Market A...
BIC LEN HIV Treatment: New Single-Tablet Regimen Shows Promising Results in A...
Novo Nordisk Announces Semaglutide Price Reduction to Improve Patient Access
NICE Approves Ruxolitinib Cream for Treating Vitiligo with Facial Involvement
SAHPRA GMP Compliance: Addressing Allegations Against Adcock Ingram’s C...
Economic Impact of Industry Clinical Trials in Europe
Merck Portfolio Optimization: Strategic Reorganization for Enhanced Commercia...
Economic Burden NSCLC: A Systematic Review of Healthcare Costs and Resource U...
Enhancing Systematic Reviews: AI Literature Review Integration for Efficiency...
Administrative Court Error Complicates Infarmed Vaccine Data Transparency